Compugen醫療 CGEN 深 滬
已收盤 02-06 16:00:00 美东时间
1.67
+0.080
+5.03%
華盛通- 最 高1.71
- 今 開1.61
- 成交量 29.63万股
- 最 低 1.601
- 昨 收 1.59
- 總市值 1.56亿
- 52周最高 2.38
- 市盈率 靜 --
- 換手率 0.32%
- 52周最低 1.13
- 委 比 -45.94%
- 總股本 9353.54万
- 歷史最高 19.90
- 量 比 1.12
- 振 幅 6.86%
- 歷史最低 0.51
- 每 手 1
- 風險率 0.25%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 瑞银上调美光科技目标价从300美元升至400美元；Freedom上调百度目标价从120美元升至160美元
今日重点评级关注：Needham：维持Vaxcyte"买入"评级，目标价从90美元升至110美元；Citizens: 维持LGI Homes"跑赢大市"评级，目标价从85美元升至95美元
01-08 18:33
HC Wainwright & Co. Initiates Coverage On Compugen with Buy Rating, Announces Price Target of $4
HC Wainwright & Co. analyst Swayampakula Ramakanth initiates coverage on Compugen (NASDAQ:CGEN) with a Buy rating and announces Price Target of $4.
01-07 19:49
Compugen rises on royalty deal with AstraZeneca
Shares of Compugen (CGEN) added ~16% in the premarket on Wednesday after the Israel-based biotech announced an agreement with AstraZeneca (AZN) to monetize a portion of future royalties linked to its ...
2025-12-17 20:58
Compugen Agrees With AstraZeneca To Monetize Portion Of Compugen's Rilvegostomig Future Royalties
Non-dilutive strategic transaction expected to extend cash runway into 2029, to advance Compugen's innovative immuno-oncology pipeline and to reach potential key catalysts from internal and partnered programsMonetization
2025-12-17 20:03
Gilead and Arcus halt late-stage study for anti-TIGIT cancer drug
Arcus Biosciences (RCUS) fell ~14% in the premarket on Friday after the company announced the discontinuation of a Phase 3 trial designed to evaluate its anti-TIGIT therapy domvanalimab in gastric and...
2025-12-12 22:13
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers GT Biopharma (NASDAQ:GTBP) shares moved upwards by 6.6% to $0.65 durin...
2025-12-06 05:05
Earnings Scheduled For November 10, 2025
Companies Reporting Before The Bell • CBAK Energy Tech (NASDAQ:CBAT) is likely ...
2025-11-10 19:12
Compugen to Release Third Quarter 2025 Results on Monday, November 10, 2025
HOLON, Israel, Oct. 27, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in predictive computational drug target di...
2025-10-27 19:00
Compugen Publishes Pooled Data Showing COM701 Activity in Platinum-Resistant Ovarian Cancer Ahead of ESMO Presentation
Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational target discovery powered by AI/ML, today announced that pooled analysis of
2025-10-13 19:10
Compugen to Present at SITC 2025
HOLON, Israel, Oct. 6, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational target discovery...
2025-10-06 19:00
